TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28299472

Group type: EXPERIMENTAL
Intervention: Ostomy rod use
Number of subjects: 320

Group type: COMPARATOR
Intervention: No ostomy rod use
Number of subjects: 320
Study: 25108027

Group type: EXPERIMENTAL
Intervention: BCG vaccination at 8 weeks of age
Number of subjects: 56

Group type: COMPARATOR
Intervention: BCG vaccination at birth
Number of subjects: 56
Study: 23551723

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (1 day/week)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (more than 1 day/week)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 79
Study: 22174778

Group type: EXPERIMENTAL
Intervention: EPA-rich supplementation
Number of subjects: 22

Group type: COMPARATOR
Intervention: DHA-rich supplementation
Number of subjects: 22
Study: 18318566

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of dutasteride and tamsulosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination therapy (Dutasteride + Tamsulosin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study: 16432269

Group type: EXPERIMENTAL
Intervention: 10-mg rizatriptan orally disintegrating tablet with water (ODTc)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10-mg rizatriptan orally disintegrating tablet without water (ODTs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 10-mg rizatriptan tablet
Number of subjects: 24
Study: 12925545

Group type: EXPERIMENTAL
Intervention: Computerized support system for symptom management
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no computerized support system)
Number of subjects: 52
Study: 11012556

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (30 microg ethinylestradiol and 75 microg gestodene)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8703457

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (F) 1 microgram/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (F)
Number of subjects: 44
Study: 1393074

Group type: EXPERIMENTAL
Intervention: 1 ml of 1% lignocaine at 20 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 ml of 1% lignocaine at 37 degrees C
Number of subjects: 40
Study: 3996632

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic intervention (interview with psychotherapist)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no psychotherapeutic intervention)
Number of subjects: 20
Study: 29699812

Group type: EXPERIMENTAL
Intervention: High-cholesterol/high-fat diet (HChF)
Number of subjects: 14
Study: 27003829

Group type: EXPERIMENTAL
Intervention: Optimal doses of renin-angiotensin system blockers (monotherapy or dual blockade)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Highest levels of TNFR1
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Baseline proteinuria
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers treatment
Number of subjects: 101
Study: 25822242

Group type: EXPERIMENTAL
Intervention: JASPER intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: PEI intervention
Number of subjects: 86
Study: 23160758

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 50 U
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100 U
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 200 U
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 22003217

Group type: EXPERIMENTAL
Intervention: sevoflurane‐remifentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: propofol‐remifentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cerebral State Monitor™ (CSM)
Number of subjects: 40
Study: 18555574

Group type: EXPERIMENTAL
Intervention: Rebaudioside A (1000mg/day for 4 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16472283

Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg once daily for 7 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg twice daily for 7 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: levofloxacin 500 mg once daily for 7 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 13
Study: 15290734

Group type: EXPERIMENTAL
Intervention: 3 g MaxEPA (omega-3 fish oils)
Number of subjects: 52

Group type: COMPARATOR
Intervention: 3 mg copper
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo fish oil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo copper
Number of subjects: 52
Study: 11263764

Group type: EXPERIMENTAL
Intervention: Strength training (50-70% of repetition maximum, all major muscle groups, twice a week)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Range of motion exercises (without resistance, twice a week)
Number of subjects: 70
Study: 9307638

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) modified grid laser photocoagulation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Argon green (514 nm) modified grid laser photocoagulation
Number of subjects: 91
Study: 8519111

Group type: EXPERIMENTAL
Intervention: Systematic antibiotics (SAs)
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Gentamicin bone cement (GBC)
Number of subjects: 1688
Study: 3548440

Group type: EXPERIMENTAL
Intervention: Adenosine (5.1 mg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 29610408

Group type: EXPERIMENTAL
Intervention: Receiving intervention services
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Perceived developmental delay
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Not having a sibling in the home
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Parents with at least a college education
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Low levels of parental stress
Number of subjects: 147
Study: 26211422

Group type: EXPERIMENTAL
Intervention: Cervical and scapulothoracic stabilization exercises with connective tissue massage (Group 1, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cervical and scapulothoracic stabilization exercises without connective tissue massage (Group 2, n = 30)
Number of subjects: 60
Study: 24901080

Group type: EXPERIMENTAL
Intervention: Oral glucose load
Number of subjects: 0
Study: 20146111

Group type: EXPERIMENTAL
Intervention: Peer-based symptom management intervention (seven peer-led sessions over seven weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control condition (received a copy of HIV Symptom Management Strategies: A Manual for People Living with HIV/AIDS)
Number of subjects: 89
Study: 18979975

Group type: EXPERIMENTAL
Intervention: Anti-smoking PSAs
Number of subjects: 166
Study: 16477955

Group type: EXPERIMENTAL
Intervention: Alert group (MSLT > 10 minutes)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sleepy-Alert group (MSLT < 7 minutes, subjective sleepiness < 1 SD above mean)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sleepy-Sleepy group (MSLT < 7 minutes, subjective sleepiness > 1 SD above mean)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alert group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sleepy-Alert group
Number of subjects: 50
Study: 11709484

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Number of subjects: 0
Study: 9146328

Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated circuit (n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carmeda BioActive Surface heparin-coated circuit (n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncoated circuit (n = 10)
Number of subjects: 40
Study: 8174879

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GRP at dosages of 10, 40, and 160 pmol/kg per hour
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study: 2885344

Group type: EXPERIMENTAL
Intervention: Buspirone 10 to 30 mg daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam 10 to 30 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29494855

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily for 90 days)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (conventional secondary preventive therapy for ischemic stroke)
Number of subjects: 404
Study: 27728850

Group type: EXPERIMENTAL
Intervention: HPV vaccination after Pap test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 0
Study: 24196521

Group type: EXPERIMENTAL
Intervention: Resistance circuit training (6 stations, 3 days per week for 12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (16 age-, sex-, and BMI-matched adults with Down syndrome)
Number of subjects: 40
Study: 21641365

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study: 19365563

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study: 16442926

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intervention (control group not explicitly mentioned)
Number of subjects: 70
Study: 15234407

Group type: EXPERIMENTAL
Intervention: mibefradil 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: mibefradil 100 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 11509483

Group type: EXPERIMENTAL
Intervention: Postocclusive reactive hyperemia in hypertensive subjects
Number of subjects: 52

Group type: COMPARATOR
Intervention: Postocclusive reactive hyperemia in normotensive subjects
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Venous occlusion in hypertensive subjects
Number of subjects: 52

Group type: COMPARATOR
Intervention: Venous occlusion in normotensive subjects
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postocclusive hyperemia in hypertensive subjects
Number of subjects: 52

Group type: COMPARATOR
Intervention: Postocclusive hyperemia in normotensive subjects
Number of subjects: 52
Study: 9210690

Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 54

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 54
Study: 8386969

Group type: EXPERIMENTAL
Intervention: Single magnetic coil (MC) pulses applied over human calcarine cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of 2 or 3 MC pulses at intervals of 0-60 ms or more than 140 ms after the visual stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First MC pulse delivered 120 ms or later, followed by a second MC pulse 40 ms later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual recovery of 5-character words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random letters vs. arbitrary linear patterns
Number of subjects: 0
Study: 3144919

Group type: EXPERIMENTAL
Intervention: Subdermal estradiol pellets (25 mg, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transdermal estradiol patch (0.1 mg, n = 10)
Number of subjects: 20
Study: 28479329

Group type: EXPERIMENTAL
Intervention: Neutrophilic asthma
Number of subjects: 167
Study: 28464935

Group type: EXPERIMENTAL
Intervention: Facilitated implementation (receive outside assistance)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard implementation (receive minimal assistance)
Number of subjects: 25
Study: 25547414

Group type: EXPERIMENTAL
Intervention: RTS,S vaccination
Number of subjects: 291

Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 291
Study: 22428541

Group type: EXPERIMENTAL
Intervention: 10 consecutive cases of unilateral cleft lip repairs
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 27 consecutive cases of unilateral cleft lip repairs
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Postoperative evaluations
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cleft severity evaluations
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cleft severity correlation with outcomes
Number of subjects: 39
Study: 21255977

Group type: EXPERIMENTAL
Intervention: Nutricia preOp (400 mL; 50.4 g carbohydrates; 260 mOsm/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Roosvicee Original (400 mL; 48 g carbohydrates; 805 mOsm/kg)
Number of subjects: 8
Study: 18976892

Group type: EXPERIMENTAL
Intervention: Cast immobilization of the ankle
Number of subjects: 62

Group type: COMPARATOR
Intervention: Symptomatic treatment with no immobilization
Number of subjects: 62
Study: 22949472

Group type: EXPERIMENTAL
Intervention: Blood pressure variability (BPV) measured by various metrics (maximum, standard deviation, coefficient of variation, successive variation, standard deviation independent of mean, successive variation independent of mean)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Blood pressure variability (BPV)
Number of subjects: 720
Study: 15499622

Group type: EXPERIMENTAL
Intervention: Dietary supplement (verum) containing plant estrogens, antioxidants, including carotenoids, selenium, administered for 6 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Dietary supplement (verum)
Number of subjects: 37
Study: 12056038

Group type: EXPERIMENTAL
Intervention: Cernilton
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87

Group type: COMPARATOR
Intervention: BPH group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Chronic prostatitis group
Number of subjects: 87
Study: 9659026

Group type: EXPERIMENTAL
Intervention: 22 G cannula
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20 G cannula
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of both cannulae
Number of subjects: 25
Study: 7868459

Group type: EXPERIMENTAL
Intervention: Sprint training (2-3 times per week for 6 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sprint training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 2732892

Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg) administered at 9 am
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg) administered at 7 pm
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered at 9 am
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo administered at 7 pm
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg) administered at both times
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hormonal levels measured before and after trial
Number of subjects: 25
Study: 4920541

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 221
Study: 30482192

Group type: EXPERIMENTAL
Intervention: Music therapy (up to six individual sessions over 3 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study: 28486023

Group type: EXPERIMENTAL
Intervention: rSO2 arm (transcranial oxygen saturation threshold > 60%)
Number of subjects: 102

Group type: COMPARATOR
Intervention: hemoglobin arm (maintaining hemoglobin between 85 and 100 g/L)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: rSO2 arm
Number of subjects: 102

Group type: COMPARATOR
Intervention: hemoglobin arm
Number of subjects: 102
Study: 25063574

Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmia bursts (VABs)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Microcirculation (MBG 2/3) restoration
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: VABs in patients with MBG 2/3
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Reperfusion VABs
Number of subjects: 154
Study: 23465304

Group type: EXPERIMENTAL
Intervention: Postvisit contact by e-mail or telephone
Number of subjects: 1350

Group type: COMPARATOR
Intervention: No postvisit contact (control)
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: E-mail contact
Number of subjects: 1350

Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 1350
Study: 24800362

Group type: EXPERIMENTAL
Intervention: Alfuzosin HCI 5 mg twice daily in addition to conventional treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (Diclofenac sodium, Anti Spasmodic (Drotverine HCl), Proton Pump inhibitor (Omeprazole 20 mg) once daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfuzosin group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 18317253

Group type: EXPERIMENTAL
Intervention: APOE genotype disclosure
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Numerical lifetime risk estimates
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (no genotype disclosure)
Number of subjects: 162
Study: 17129496

Group type: EXPERIMENTAL
Intervention: SIT with standardized house dust mite (HDM) vaccine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 12840632

Group type: EXPERIMENTAL
Intervention: AA genotype
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: Upper tertile of % high-intensity activity
Number of subjects: 1720

Group type: COMPARATOR
Intervention: CETP 1b.‐629 x % high‐intensity activity interaction
Number of subjects: 1720
Study: 11054330

Group type: EXPERIMENTAL
Intervention: Superior incision group
Number of subjects: 87

Group type: COMPARATOR
Intervention: Temporal incision group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 8626986

Group type: EXPERIMENTAL
Intervention: Credit card asthma self-management plan
Number of subjects: 30
Study: 1345134

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 194
Study: 6541538

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 102
Study: 31375814

Group type: EXPERIMENTAL
Intervention: Indirect bonding technique
Number of subjects: 56

Group type: COMPARATOR
Intervention: Direct bonding technique
Number of subjects: 56
Study: 29997294

Group type: EXPERIMENTAL
Intervention: Oral norovirus vaccine (single dose)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27542703

Group type: EXPERIMENTAL
Intervention: High-hydration (HiH) status (USG < 1.015)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-hydration (LoH) status (USG ≥ 1.015)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urine specific gravity (USG)
Number of subjects: 50
Study: 25601335

Group type: COMPARATOR
Intervention: Single fractions of 1.0 Gy applied two times a week, for a total dose of 6.0 Gy (total therapy time: 3 weeks)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Single fractions of 0.5 Gy applied 3 times a week, for a total dose of 6.0 Gy (total therapy time: 4 weeks)
Number of subjects: 240
Study: 23928902

Group type: EXPERIMENTAL
Intervention: Flublok® (trivalent influenza vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flublok®
Number of subjects: 0
Study: 21037989

Group type: EXPERIMENTAL
Intervention: Imprint cytology technique
Number of subjects: 273

Group type: COMPARATOR
Intervention: Gram-stained smear
Number of subjects: 273

Group type: COMPARATOR
Intervention: Rapid urease test
Number of subjects: 273

Group type: COMPARATOR
Intervention: Culture methods
Number of subjects: 273

Group type: COMPARATOR
Intervention: Combination of Gram-stained smear, rapid urease test, and culture methods
Number of subjects: 273
Study: 18218297

Group type: EXPERIMENTAL
Intervention: Moisture-resistant tablet (dextran formulation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard tablet (lactose formulation)
Number of subjects: 120
Study: 16608513

Group type: EXPERIMENTAL
Intervention: rt-PA 1 mg per lumen once per week
Number of subjects: 340

Group type: COMPARATOR
Intervention: Heparin 5,000 units per ml as a catheter locking solution after each dialysis session
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of rt-PA as a locking solution
Number of subjects: 340
Study: 14993717

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 120
Study: 11689299

Group type: EXPERIMENTAL
Intervention: Shaping with visual feedback stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-paced button pressing without reinforcement
Number of subjects: 0
Study: 9145877

Group type: EXPERIMENTAL
Intervention: Cefotaxime monotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefotaxime and Ofloxacin combination therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ofloxacin monotherapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ofloxacin and Cefotaxime combination therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 12
Study: 7679532

Group type: EXPERIMENTAL
Intervention: 15 mg of urapidil b.i.d. for 3 weeks (group L)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 15 mg b.i.d. for 1 week followed by 30 mg b.i.d. for 2 weeks (group M)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: 15 mg b.i.d. for 1 week followed by 45 mg b.i.d. for 2 weeks (group H)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 214
Study: 3497380

Group type: EXPERIMENTAL
Intervention: Hib capsular polysaccharide vaccine (Connaught)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hib capsular polysaccharide vaccine (Praxis)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Both vaccines (Connaught and Praxis)
Number of subjects: 85
Study: 29506692

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both AIT and ACT
Number of subjects: 200